Earnings call transcript: Devyser Diagnostics Q1 2026 shows robust growth

Devyser Diagnostics posted Q1 2026 revenue of SEK 62 million, up 13% year over year, with EBIT turning positive at SEK 2.6 million versus SEK -14.8 million last year, marking a fourth consecutive profitable quarter. Gross margin remained strong at 81.6% and operating cash flow was SEK 12 million, while the stock rose 3.24% to SEK 92.4 after the announcement. Management highlighted momentum from IVDR product launches, Illumina and Thermo Fisher collaborations, and the Cybergene acquisition, though FX headwinds and regional logistics risks remain.

Analysis

Devyser is transitioning from a single-quarter earnings beat into a more durable operating inflection: the key signal is not the modest revenue growth rate, but the combination of positive EBIT, positive operating cash flow, and management confidence that growth is becoming less lumpy. That matters because the stock is likely to re-rate on proof of operating leverage rather than on headline top-line acceleration alone. The market is underestimating how much the margin profile can expand if Cybergene contributes higher gross margin mix without requiring material incremental opex.

The bigger second-order effect is channel validation. Illumina and Thermo are not just distribution wins; they are demand-creation levers that can compress customer acquisition cost and de-risk adoption in fragmented European clinical genomics markets. If those partnerships convert into repeatable customer onboarding, Devyser’s revenue mix should shift toward higher-visibility, lower-churn reagent rental and transplant workflows, which can support a premium multiple even before U.S. reimbursement inflects.

The main risk is that the market is extrapolating too quickly from an improving quarter into a straight-line earnings model. FX remains a real reported-growth headwind, and the current valuation likely already discounts continued execution on IVDR launches and MolDX progress. If Q2/Q4 seasonality normalizes without an obvious step-up from Illumina/Thermo, the stock can consolidate even while fundamentals improve; the catalyst window is therefore 1-2 quarters, not days.

Contrarian view: consensus may be over-focusing on whether Devyser can stay profitable and underpricing the option value of becoming a platform supplier to large diagnostics ecosystems. The bear case is that partnerships remain symbolic and volume ramps slowly; the bull case is that these deals create an embedded distribution layer that accelerates every subsequent launch. For now, the risk/reward still favors upside because operating leverage is visible before the full partnership economics are.

Key Decisions for Investors

• Long DVYSR on pullbacks over the next 2-6 weeks; thesis is that the market is still underpricing sustained EBIT positivity and cash generation. Risk/reward favors 15-20% upside if Q2 shows even partial conversion of the Illumina/Thermo pipeline; downside is limited to a mid-teens multiple reset if seasonality disappoints.
• Buy a 3-6 month call spread on DVYSR if listed liquidity allows; structure it around the next two earnings dates to capture partnership monetization and MolDX optionality while capping premium burn if conversion is delayed.
• Pair trade: long DVYSR / short a more mature diagnostics name with slower growth and lower operating leverage. The relative-value case is that Devyser is earlier in the re-rating cycle, while the short leg should have less upside from operational surprise.
• Add ILMN as a tactical beneficiary, but only as a low-conviction sympathy long. Devyser’s deal modestly strengthens Illumina’s ecosystem narrative; upside is limited, but the partnership reduces standalone commercial execution risk around sequencing workflows.
• Watch for a breakout trade only after the next evidence point on U.S. customer onboarding or post-launch IVDR uptake. If revenue growth holds in local currency and margin stays above 80%, increase exposure; if not, reduce before the market starts pricing in a slower normalization.